- In June 2023, Novartis announced its agreement to acquire Chinook Therapeutics, a clinical-stage biopharmaceutical company. This move aligns with Novartis's strategy to introduce new medicines and enhance its renal portfolio
- In April 2023, GSK plc presented positive results from the EAGLE-2 and EAGLE-3 clinical trials for gepotidacin. This phase III success highlights the potential of gepotidacin as the first-in-class oral antibiotic for treating uncomplicated urinary tract infections (uUTIs) in female adolescents and adults
- In March 2023, Pfizer Inc. disclosed a definitive merger agreement with Seagen Inc., a biotechnology leader in developing and commercializing cancer treatments and a pioneer in antibody-drug conjugate (ADC) technology
- In March 2022, Novartis announced the approval of Pluvicto, a treatment for prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC). The therapy is expected to significantly improve survival rates for patients with limited treatment options
- In July 2021, AiCuris Anti-infective Cures AG initiated a phase III clinical trial for pritelivir to treat immunocompromised individuals with HSV. This development reflects ongoing collaborative research by major pharmaceutical companies to maintain leadership in the branded genitourinary drugs market
